Sara Monteiro-Reis

TL;DR: The results support a proto-oncogenic role for SMYD3 in prostate carcinogenesis, mainly due to its methyltransferase enzymatic activity, and suggestSMYD3 overexpression is a potential biomarker for clinically aggressive disease and an attractive therapeutic target in PCa.

TL;DR: The data shows that sirtuins are deregulated in EC, and the diversity of expression patterns observed suggests that sIRTuins may have distinctive roles in endometrial cancer similarly to what has been described in other cancer models.

TL;DR: GDF15, TMEFF2 and V IM promoter methylation allows for accurate identification of UTUC, in tissue and urine and VIM methylation provides relevant prognostic information, especially in high-stage disease.

TL;DR: TERT promoter mutations detected by the UroMuTERT assay in urinary DNA (cfDNA or cellDNA) show excellent sensitivity and specificity for the detection of UC, significantly outperforming that of urine cytology notably for detection of low-grade early stages UC.

TL;DR: The results demonstrate that a GC–MS metabolomics-based approach for analysis of VOCs is a valuable strategy for identifying new and specific biomarkers that may improve BC diagnosis and validate the validation of volatile signature found for BC cell lines in biofluids from BC patients.